Scrip Asks…What Does 2022 Hold For Biopharma? Part 4: Therapeutic Area Advances
High Hopes In COVID-19, Cancer, CNS, Immunology And Rare Disease
Executive Summary
Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the pharma industry reacts to the Ukraine situation; a guide to targeted protein degradation; Janssen/Legend’s US pricing and launch plans for Carvykti; Ipsen seeks multiple licensing deals; and the fourth in the Scrip Asks series looks at prospects for therapeutic advances.
Scrip Asks…What Does 2022 Hold For Biopharma? Part 7: People And Planet
Addressing health care inequities, providing a nurturing environment for employees and learning from the pandemic were among the aims expressed by executives surveyed by Scrip.
Scrip Asks…What Does 2022 Hold For Biopharma? Part 6: Digital And Telehealth
Digital and telehealth solutions took off during COVID-19 and industry observers expect them to advance still further in the coming year. Coupling enhanced patient experience with rich opportunities to use associated data to enhance product development and health care practice, benefits should accrue to industry, health care practitioners, health systems and patients alike.